دورية أكاديمية
Acceptability of a Future HIV Vaccine: A Rapid Scoping Review.
| العنوان: | Acceptability of a Future HIV Vaccine: A Rapid Scoping Review. |
|---|---|
| المؤلفون: | Choi J; Department of Health Promotion and Behavioral Sciences, The University of Texas Health Science Center at Houston School of Public Health, Houston, TX.; Center for Health Promotion and Prevention Research, The University of Texas Health Science Center at Houston School of Public Health, Houston, TX., May SB; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX., Dang BN; Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX.; VA Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX; and., Markham C; Department of Health Promotion and Behavioral Sciences, The University of Texas Health Science Center at Houston School of Public Health, Houston, TX.; Center for Health Promotion and Prevention Research, The University of Texas Health Science Center at Houston School of Public Health, Houston, TX., McGlone M; Department of Communication Studies, Moody College of Communication, The University of Texas at Austin, Austin, TX., Cuccaro PM; Department of Health Promotion and Behavioral Sciences, The University of Texas Health Science Center at Houston School of Public Health, Houston, TX.; Center for Health Promotion and Prevention Research, The University of Texas Health Science Center at Houston School of Public Health, Houston, TX. |
| المصدر: | Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2024 Jul 01; Vol. 96 (3), pp. 197-207. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins, Inc Country of Publication: United States NLM ID: 100892005 Publication Model: Print Cited Medium: Internet ISSN: 1944-7884 (Electronic) Linking ISSN: 15254135 NLM ISO Abbreviation: J Acquir Immune Defic Syndr Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins, Inc., c1999- |
| مواضيع طبية MeSH: | AIDS Vaccines*/administration & dosage , HIV Infections*/prevention & control , Patient Acceptance of Health Care*, Humans ; Social Stigma ; Health Knowledge, Attitudes, Practice |
| مستخلص: | Background: A HIV vaccine is not available yet, but perceptions of HIV vaccines will be important to explore before their roll-out for effective vaccine promotion. This article presents the findings of a rapid scoping review of the literature to identify individual, social, and vaccine-related factors associated with the acceptability of a future HIV vaccine. Methods: We searched 5 databases (Medline OVID, Embase, PsycINFO, Web of Science, and Cochrane) using relevant keywords and Medical Subject Headings. All articles, regardless of study design, publication year, and geographic location, were included if they examined HIV vaccine acceptability and its underlying factors. Results: We retrieved 2386 unique articles, of which 76 were included in the final review. Perceived benefits (34.2%) and perceived susceptibility (25.0%) were primary individual factors of HIV vaccine acceptability. Misinformation (17.1%) and distrust (22.4%) regarding future HIV vaccines, HIV stigma (30.3%), and social support (10.5%) were social factors of HIV vaccine acceptability. Vaccine efficacy (42.1%), cost (28.9%), and side effects (67.1%) were common vaccine characteristics influencing HIV vaccine acceptability. Altruism (10.5%) and risk compensation (26.3%) were also key factors. Conclusions: Our analyses revealed that skeptical beliefs, negative perceptions, and misconceptions about HIV vaccines are real barriers to their acceptability. To alleviate HIV vaccine hesitancy and address trust concerns, strategic vaccine communication should be disseminated by trustworthy sources. Messages should impart accurate vaccine information and emphasize both individual and social benefits of HIV vaccination, as well as leverage social support in increasing willingness to get a future HIV vaccine. Competing Interests: The authors have no conflicts of interest to disclose. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Global HIV, AIDS Statistics—Fact Sheet. 2023. Available at: https://www.unaids.org/en/resources/fact-sheet. Accessed October 25, 2023. Pandey A, Galvani AP. The global burden of HIV and prospects for control. Lancet HIV. 2019;6:e809–e811. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS One. 2014;9:e86584. Barré-Sinoussi F, Ross AL, Delfraissy JF. Past, present and future: 30 years of HIV research. Nat Rev Microbiol. 2013;11:877–883. Ng'uni T, Chasara C, Ndhlovu ZM. Major scientific hurdles in HIV vaccine development: historical perspective and future directions. Front Immunol. 2020;11:590780. Fauci AS. An HIV vaccine is essential for ending the HIV/AIDS pandemic. JAMA. 2017;318:1535–1536. Coy KC, Hazen RJ, Kirkham HS, et al. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. J Int AIDS Soc. 2019;22:e25252. Bekker LG, Tatoud R, Dabis F, et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet. 2020;395:384–388. Newman PA, Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS. 2010;24:1749–1756. Joshi A, Kaur M, Kaur R, et al. Predictors of COVID-19 vaccine acceptance, intention, and hesitancy: a scoping review. Front Public Health. 2021;9:698111. Hoque AM, Buckus S, Hoque M, et al. COVID-19 vaccine acceptability among pregnant women at a primary health care facility in Durban, South Africa. Eur J Med Health Sci. 2020;2(5):1–6. Newman PA, Dinh DA, Nyoni T, et al. Covid-19 vaccine hesitancy and under-vaccination among marginalized populations in the United States and Canada: A scoping review. J Racial Ethn Health Disparities. 2023. doi:10.1007/s40615-023-01882-1. 38117443. (PMID: 10.1007/s40615-023-01882-1) Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467–473. Connochie D, Tingler RC, Bauermeister JA. Young men who have sex with men's awareness, acceptability, and willingness to participate in HIV vaccine trials: results from a nationwide online pilot study. Vaccine. 2019;37:6494–6499. Buchbinder SP, Metch B, Holte SE, et al. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36:604–612. Malahleha M, Dilraj A, Jean J, et al. Exploring a community's understanding of HIV vaccine-induced seropositivity in a South African research setting. S Afr Med J. 2022;113:36–41. Dimi S, Zucman D, Chassany O, et al. Patients' high acceptability of a future therapeutic HIV vaccine in France: a French paradox? BMC Infect Dis. 2019;19:401. Painter JE, Temple BS, Woods LA, et al. Theory-based analysis of interest in an HIV vaccine for reasons indicative of risk compensation among African American women. Health Educ Behav. 2018;45:444–453. Esber AL, Jansen K, Dorsey-Spitz J, et al. Preparing for future European efficacy trials of interventions to prevent HIV and other sexually transmitted infections: lessons on willingness to participate and barriers to participation from ten German clinics serving behaviorally vulnerable men who have sex with men. Vaccine X. 2023;14:100302. Iseselo MK, Tarimo EA, Sandstrom E, et al. What motivates or demotivates injecting drug users to participate in hypothetical HIV vaccine efficacy trials? A qualitative study from urban Tanzania. East Afr Health Res J. 2020;4:128–139. Chuang DM, Newman PA, Weaver J. HIV vaccine preparedness among men who have sex with men in Taiwan: sociocultural and behavioral factors. J Int Assoc Provid AIDS Care. 2019;18:2325958219832285. Lee SJ, Newman PA, Comulada WS, et al. Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences. Int J STD AIDS. 2012;23:235–241. Painter J, Cene-Kush C, Conner A, et al. Anticipated HIV vaccine acceptability among sexually active African-American adult women. Vaccines (Basel). 2013;1:88–104. Newman PA, Roungprakhon S, Tepjan S, et al. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine. 2010;28:958–964. Sayles JN, Macphail CL, Newman PA, et al. Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav. 2010;37:193–210. Lally M, Gaitanis M, Vallabhaneni S, et al. Willingness to receive an HIV vaccine among incarcerated persons. Prev Med. 2006;43:402–405. Newman PA, Duan N, Lee SJ, et al. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine. 2006;24:2094–2101. Roberts KJ, Newman PA, Duan N, et al. HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion. J Natl Med Assoc. 2005;97:1662–1671. Zimet GD, Perkins SM, Sturm LA, et al. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health. 2005;37:179–186. Kakinami L, Newman PA, Lee SJ, et al. Differences in HIV vaccine acceptability between genders. AIDS Care. 2008;20:542–546. Suhadev M, Nyamathi AM, Swaminathan S, et al. A pilot study on willingness to participate in future preventive HIV vaccine trials. Indian J Med Res. 2006;124:631–640. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785–793. Zimet GD, Liau A, Fortenberry VD. Health beliefs and intention to get immunized for HIV. J Adolesc Health. 1997;20:354–359. Newman PA, Roungprakhon S, Tepjan S, et al. A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Glob Public Health. 2012;7:1009–1024. Williams CC, Newman PA, Sakamoto I, et al. HIV prevention risks for Black women in Canada. Soc Sci Med. 2009;68:12–20. Lindegger G, Quayle M, Ndlovu M. Local knowledge and experiences of vaccination: implications for HIV-preventive vaccine trials in South Africa. Health Educ Behav. 2007;34:108–123. Barrington C, Moreno L, Kerrigan D. Local understanding of an HIV vaccine and its relationship with HIV-related stigma in the Dominican Republic. AIDS Care. 2007;19:871–877. Richardson S, Seekaew P, Koblin B, et al. Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City. PLoS One. 2017;12:e0181702. Fleming T, Valleriani J, Ng C, et al. Acceptability of a hypothetical preventative HIV vaccine among people who use drugs in Vancouver, Canada. BMC Public Health. 2020;20:1081. Starace F, Wagner TM, Luzi AM, et al. Knowledge and attitudes regarding preventative HIV vaccine clinical trials in Italy: results of a national survey. AIDS Care. 2006;18:66–72. Newman PA, Duan N, Rudy ET, et al. HIV risk and prevention in a post-vaccine context. Vaccine. 2004;22:1954–1963. Barrington C, Moreno L, Kerrigan D. Perceived influence of an HIV vaccine on sexual-risk behaviour in the Dominican Republic. Cult Health Sex. 2008;10:391–401. Nanvubya A, Mpendo J, Ssetaala A, et al. Willingness to participate in HIV vaccine efficacy trials in a population of fishing communities, Uganda. Retrovirology. 2012;9:P235. Allen MA, Liang TS, La Salvia T, et al. Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. J Acquir Immune Defic Syndr. 2005;40:617–624. Chakrapani V, Newman PA, Singhal N, et al. “If It's Not Working, Why Would They Be Testing It?”: mental models of HIV vaccine trials and preventive misconception among men who have sex with men in India. BMC Public Health. 2013;13:731. Doshi M, Avery L, Kaddu RP, et al. Contextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials. BMC Public Health. 2017;17:469. Malahleha M, Malamatsho R, Mbatsane E, et al. Exploring community understanding of HIV vaccine-induced seropositivity in Soshanguve, South Africa. 4th HIV Research for Prevention Conference (HIVR4P/Virtual), January 27 and 28, 2021, February 3 and 4, 2021. Cecchini D, Ballivian J, Feld D, et al. Barriers for participation in HIV vaccine trials among general population in Argentina: first interim study. HIV Glasgow—Virtual, October 5–8, 2020. Newman PA, Woodford MR, Logie C. HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada. Glob Public Health. 2012;7:87–100. Farquhar C, John-Stewart GC, John FN, et al. Pediatric HIV type 1 vaccine trial acceptability among mothers in Kenya. AIDS Res Hum Retroviruses. 2006;22:491–495. Priddy FH, Cheng AC, Salazar LF, et al. Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US. Int J STD AIDS. 2006;17:99–102. Newman PA, Duan N, Roberts KJ, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr. 2006;41:210–217. Lee SJ, Brooks RA, Newman PA, et al. HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care. 2008;20:1161–1168. Koblin BA, Avrett S, Taylor PE, et al. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: project ACHIEVE. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:165–171. Celentano DD, Beyrer C, Natpratan C, et al. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS. 1995;9:1079–1083. Tello J, Soong SJ, Hunter B, et al. HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic. Am J Med Sci. 1998;315:11–16. du Plessis E, Kaddu RP, Doshi M, et al. Mistrust, misunderstandings, and corruption: exploring the socio-cultural and political factors of HIV vaccine acceptability in Kenya. Canadian Association for HIV Research Annual, Vancouver, Canada, April 11–14, 2013. Frew PM, Crosby RA, Salazar LF, et al. Acceptance of a potential HIV/AIDS vaccine among minority women. J Natl Med Assoc. 2008;100:802–813. Gagnon MP, Godin G. Young adults and HIV vaccine: determinants of the intention of getting immunized. Can J Public Health. 2000;91:432–434. Hom DL, Johnson JL, Mugyenyi P, et al. HIV-1 risk and vaccine acceptability in the Ugandan military. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:375–380. Koniak-Griffin D, Nyamathi A, Tallen L, et al. Breaking the silence: what homeless 18- to 24-year-olds say about HIV vaccine trials. J Health Care Poor Underserved. 2007;18:687–698. Kpanake L, Gbandey S, Sorum PC, et al. Acceptability of vaccination against HIV: a mapping of Togolese people's positions. J Health Psychol. 2018;23:800–806. Lee SJ, Newman PA, Duan N, et al. Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES. Vaccine. 2014;32:5013–5018. Liau A, Zimet GD, Fortenberry JD. Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics. Sex Transm Dis. 1998;25:76–81. Liau A, Zimet GD. Undergraduates' perception of HIV immunization: attitudes and behaviours as determining factors. Int J STD AIDS. 2000;11:445–450. Liau A, Zimet GD. The acceptability of HIV immunization: examining vaccine characteristics as determining factors. AIDS Care. 2001;13:643–650. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med. 2004;58:1405–1413. Moodley K, Barnes J, van Rensburg EJ, et al. Willingness to participate in South African HIV vaccine trials--concerns of medical professionals in the Western Cape. S Afr Med J. 2002;92:904–906. Newman PA, Duan N, Rudy ET, et al. Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr. 2004;37:1393–1403. Newman PA, Seiden DS, Roberts KJ, et al. A small dose of HIV? HIV vaccine mental models and risk communication. Health Educ Behav. 2009;36:321–333. Newman PA, Daley A, Halpenny R, et al. Community heroes or “high-risk” pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine. 2008;26:1091–1097. Newman PA, Duan N, Kakinami L, et al. What can HIV vaccine trials teach us about future HIV vaccine dissemination? Vaccine. 2008;26:2528–2536. Newman PA, Lee SJ, Duan N, et al. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res. 2009;44:2167–2179. Williamson V, Coetzee B, Kagee A, et al. Factors influencing mothers' decision to enroll their HIV-negative children in a hypothetical HIV vaccine trial. Future Virol. 2017;12:19–28. Nguyen F. Gauging the acceptability of HIV vaccines: an exploratory study examining knowledge, attitudes, and beliefs among injecting drug users in Viet Nam. J Ethnic Cult Divers Soc Work. 2007;16:161–192. Nodin N, Carballo-Diéguez A, Ventuneac AM, et al. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care. 2008;20:106–115. Olin J, Kokolamami J, Lepira FB, et al. Community preparedness for HIV vaccine trials in the Democratic Republic of Congo. Cult Health Sex. 2006;8:529–544. Ravert RD, Zimet GD. College student invulnerability beliefs and HIV vaccine acceptability. Am J Health Behav. 2009;33:391–399. Rudy ET, Newman PA, Duan N, et al. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev. 2005;17:253–267. Salazar LF, Holtgrave D, Crosby RA, et al. Issues related to gay and bisexual men's acceptance of a future AIDS vaccine. Int J STD AIDS. 2005;16:546–548. Strauss RP, Sengupta S, Kegeles S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr. 2001;26:63–71. Suhadev M, Nyamathi AM, Swaminathan S, et al. Factors associated with willingness to participate in HIV vaccine trials among high-risk populations in South India. AIDS Res Hum Retroviruses. 2009;25:217–224. Weaver J, Newman PA, Williams CC, et al. “Sisters, mothers, daughters and aunties”: HIV vaccine acceptability among African, Caribbean and other Black women in Toronto. Can J Public Health. 2013;104:e413–e417. Webb PM, Zimet GD, Mays R, et al. HIV immunization: acceptability and anticipated effects on sexual behavior among adolescents. J Adolesc Health. 1999;25:320–322. Whittington D, Suraratdecha C, Poulos C, et al. Household demand for preventive HIV/AIDS vaccines in Thailand: do husbands' and wives' preferences differ? Value Health. 2008;11:965–974. Young AM, DiClemente RJ, Halgin DS, et al. Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis. AIDS Behav. 2014;18:1753–1763. Young AM, DiClemente RJ, Halgin DS, et al. HIV vaccine acceptability among high-risk drug users in Appalachia: a cross-sectional study. BMC Public Health. 2014;14:537. Zimet G, Fortenberry J, Blythe M. Adolescents' attitudes about HIV immunization. J Pediatr Psychol. 1999;24:67–75. Zimet GD, Blythe MJ, Fortenberry JD. Vaccine characteristics and acceptability of HIV immunization among adolescents. Int J STD AIDS. 2000;11:143–149. Holmes D. FDA paves the way for pre-exposure HIV prophylaxis. Lancet. 2012;380:325. Brewer NT, Cuite CL, Herrington JE, et al. Risk compensation and vaccination: can getting vaccinated cause people to engage in risky behaviors? Ann Behav Med. 2007;34:95–99. Stephenson R, White D, Darbes L, et al. HIV testing behaviors and perceptions of risk of HIV infection among MSM with main partners. AIDS Behav. 2015;19:553–560. Leblanc NM, McMahon J. Perceived facilitators and barriers to couples' HIV testing and counseling in U.S. Clinical settings: perspectives from U.S. Health providers. J Assoc Nurses AIDS Care. 2019;30:279–291. Pinedo M, Burgos JL, Robertson AM, et al. Perceived risk of HIV infection among deported male injection drug users in Tijuana, Mexico. Glob Public Health. 2014;9:436–454. Adams LM, Stuewig JB, Tangney JP, et al. Perceived susceptibility to AIDS predicts subsequent HIV risk: a longitudinal evaluation of jail inmates. J Behav Med. 2014;37:511–523. Pugliese-Garcia M, Heyerdahl LW, Mwamba C, et al. Factors influencing vaccine acceptance and hesitancy in three informal settlements in Lusaka, Zambia. Vaccine. 2018;36:5617–5624. Searles M, Jose Ronquillo Mora Y, Carlo L, et al. Zika virus knowledge and vaccine acceptance among undergraduate students in Guayaquil, Ecuador. Vaccine X. 2023;13:100258. Grossman CI, Stangl AL. Editorial: global action to reduce HIV stigma and discrimination. J Int AIDS Soc. 2013;16:18881. Friedland BA, Sprague L, Nyblade L, et al. Measuring intersecting stigma among key populations living with HIV: implementing the people living with HIV Stigma Index 2.0. J Int AIDS Soc. 2018;21(suppl 5):e25131. Audet CM, McGowan CC, Wallston KA, et al. Relationship between HIV stigma and self-isolation among people living with HIV in Tennessee. PLoS One. 2013;8:e69564. Levi-Minzi MA, Surratt HL. HIV stigma among substance abusing people living with HIV/AIDS: implications for HIV treatment. AIDS Patient Care STDS. 2014;28:442–451. Center for Biologics Evaluation and Research. Development and licensure of vaccines to prevent COVID-19; 2023. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19. Accessed October 25, 2023. Forni G, Mantovani A; COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28:626–639. Hotez PJ, Nuzhath T, Colwell B. Combating vaccine hesitancy and other 21st century social determinants in the global fight against measles. Curr Opin Virol. 2020;41:1–7. Nicholls LAB, Gallant AJ, Cogan N, et al. Older adults' vaccine hesitancy: psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake. Vaccine. 2021;39:3520–3527. Zhao P, Liu S, Zhong Z, et al. Prevalence and genotype distribution of human papillomavirus infection among women in northeastern Guangdong Province of China. BMC Infect Dis. 2018;18:204. Stout ME, Christy SM, Winger JG, et al. Self-efficacy and HPV vaccine attitudes mediate the relationship between social norms and intentions to receive the HPV vaccine among college students. J Community Health. 2020;45:1187–1195. CDC. Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data United States and 6 Dependent Areas, 2019: National Profile; 2022. Available at: https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-26-no-2/content/national-profile.html. Accessed August 16, 2022. Jahagirdar D, Walters M, Vongpradith A, et al. Incidence of HIV in sub-Saharan Africa, 2000–2015: the interplay between social determinants and behavioral risk factors. AIDS Behav. 2021;25:145–154. Sullivan PS, Satcher Johnson A, Pembleton ES, et al. Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. Lancet. 2021;397:1095–1106. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc Biol Sci. 1993;253:9–13. Betsch C, Böhm R, Korn L, et al. On the benefits of explaining herd immunity in vaccine advocacy. Nat Hum Behav. 2017;1:1–6. Pfattheicher S, Petersen MB, Böhm R. Information about herd immunity through vaccination and empathy promote COVID-19 vaccination intentions. Health Psychol. 2022;41:85–93. Trueblood JS, Sussman AB, O'Leary D. The role of risk preferences in responses to messaging about COVID-19 vaccine take-up. Soc Psychol Personal Sci. 2022;13:311–319. James EK, Bokemper SE, Gerber AS, et al. Persuasive messaging to increase COVID-19 vaccine uptake intentions. Vaccine. 2021;39:7158–7165. Jung H, Albarracín D. Concerns for others increases the likelihood of vaccination against influenza and COVID-19 more in sparsely rather than densely populated areas. Proc Natl Acad Sci U S A. 2021;118:e2007538118. |
| المشرفين على المادة: | 0 (AIDS Vaccines) |
| تواريخ الأحداث: | Date Created: 20240621 Date Completed: 20240621 Latest Revision: 20240625 |
| رمز التحديث: | 20240625 |
| DOI: | 10.1097/QAI.0000000000003416 |
| PMID: | 38905472 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1944-7884 |
|---|---|
| DOI: | 10.1097/QAI.0000000000003416 |